LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Search

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

31.86 7.16

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

29.78

Максимум

33.06

Ключови измерители

By Trading Economics

Приходи

-339M

-94M

Продажби

-82M

32M

EPS

-0.91

Марж на печалбата

-297.177

Служители

522

EBITDA

-362M

-102M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+74.27% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-52M

3B

Предишно отваряне

24.7

Предишно затваряне

31.86

Настроения в новините

By Acuity

68%

32%

36 / 344 Класиране в Healthcare

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.05.2026 г., 21:33 ч. UTC

Печалби

Correction to Salesforce 1Q Sales, Profit Rise Article

27.05.2026 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Agrees to Buy The College of Health Care Professions

27.05.2026 г., 20:18 ч. UTC

Печалби

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27.05.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

27.05.2026 г., 23:08 ч. UTC

Пазарно говорене

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27.05.2026 г., 22:21 ч. UTC

Пазарно говорене

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27.05.2026 г., 21:29 ч. UTC

Горещи акции

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27.05.2026 г., 21:08 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27.05.2026 г., 21:02 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27.05.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27.05.2026 г., 20:55 ч. UTC

Печалби

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.05.2026 г., 20:48 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27.05.2026 г., 20:45 ч. UTC

Печалби

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27.05.2026 г., 20:34 ч. UTC

Придобивния, сливания и поглъщания

Webster Financial Stockholders Approve Sale to Banco Santander

27.05.2026 г., 20:32 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27.05.2026 г., 20:30 ч. UTC

Печалби

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27.05.2026 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27.05.2026 г., 20:22 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:16 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27.05.2026 г., 20:13 ч. UTC

Печалби

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

74.27% нагоре

12-месечна прогноза

Среден 49.91 USD  74.27%

Висок 80 USD

Нисък 26 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

11

Купи

1

Задържане

0

Продай

Настроение

By Acuity

36 / 344 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
help-icon Live chat